Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
AAPS PharmSciTech ; 18(4): 1203-1212, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-27431914

RESUMEN

Poorly water-soluble compounds have a potential risk of low and variable bioavailability caused by incomplete dissolution. Incorporation of organic acids as pH modifiers is effective method for solubility enhancement of basic compounds and requires no special technique and equipment. The purpose of this study was to evaluate the effect of manufacturing method on the extent of drug solubility enhancement. We successfully prepared the granules and tablets containing ketoconazole (KZ), which is weakly basic, as a model compound and citric acid as a pH modifier using conventional wet and dry granulations. KZ solubility under non-sink condition was enhanced with supersaturation using both wet and dry granulations. High-shear granulation was the most effective method in terms of KZ dissolution enhancement, because both an intimate contact and strong bonding between KZ and incorporated acid were achieved. KZ dissolved amount from the granules prepared by high-shear granulation was about eight times higher than that from the granules without the acid. The granulation involved to suppress a diffusion of acid dissolved, leading to the effectively maintained supersaturation state. The bioavailability of KZ after oral administration to rats was improved by applying high-shear granulation with citric acid independent of gastrointestinal pH. The granules prepared by high-shear granulation showed the bioavailability about 1.7-fold higher than that of the physical mixture in rats with and without neutralization of stomach. As a result, both the dissolution and absorption rates of KZ after oral administration were enhanced using conventional manufacturing technology.


Asunto(s)
Cetoconazol/farmacocinética , Absorción Fisiológica , Administración Oral , Animales , Disponibilidad Biológica , Química Farmacéutica , Ácido Cítrico/química , Concentración de Iones de Hidrógeno , Cetoconazol/administración & dosificación , Cetoconazol/química , Ratas , Solubilidad , Comprimidos/química , Agua/química
2.
J Pharm Sci ; 105(12): 3680-3690, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27771051

RESUMEN

Bisphosphonates (BPs) are carbon-substituted pyrophosphate analogs that exhibit a high affinity to hydroxyapatite and specifically inhibit bone resorption. Alendronate sodium (sodium 4-amino-1-hydroxybutylidene-1,1-bisphosphonate trihydrate) is a typical BP compound in clinical use. BPs have very low bioavailability, typically <1% after their oral administration, and their intestinal absorption is further reduced by co-administered drugs or food. In this study, we examined the effects of N-acyl amino acids and N-acyl taurates on the small intestinal absorption of alendronate. All N-acyl amino acids and N-acyl taurates increased the small intestinal absorption of alendronate, especially 1% (wt/vol) sodium palmitoyl sarcosinate (PN), which elicited a 14-fold increase. In addition, the absorption-enhancing effects of these enhancers were reversible and they may not cause continuous and irreversible membrane toxicity in the rat small intestine. Furthermore, we examined the absorption-promoting mechanisms of PN and found that it increased the membrane fluidity of the lipid bilayers. In addition, it was found that PN may open the tight junctions by reducing the expression level of claudin-4, which is a major tight junction protein. These findings indicate that these enhancers are useful for promoting the intestinal absorption of alendronate.


Asunto(s)
Alendronato/metabolismo , Aminoácidos/metabolismo , Difosfonatos/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Absorción Intestinal/fisiología , Administración Oral , Alendronato/administración & dosificación , Alendronato/química , Aminoácidos/administración & dosificación , Aminoácidos/química , Animales , Disponibilidad Biológica , Células CACO-2 , Difosfonatos/administración & dosificación , Difosfonatos/química , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Humanos , Absorción Intestinal/efectos de los fármacos , Intestino Delgado/efectos de los fármacos , Intestino Delgado/metabolismo , Ratas
3.
Eur J Pharm Sci ; 76: 225-30, 2015 Aug 30.
Artículo en Inglés | MEDLINE | ID: mdl-25988287

RESUMEN

Formulation development of poorly water-soluble compounds can be challenging because of incomplete dissolution that causes low and variable bioavailability. Enhancing compound solubility is important and many techniques have been investigated to that end, but they require specific materials and machinery. This study investigates the incorporation of a pH-modifier as a method to increase compound solubility and uses ketoconazole (KZ), which is weakly basic (pKa: 6.5), as a model compound. Organic acids are effective pH-modifiers and are generally used in pharmaceutical industries. We successfully obtained granules containing variable organic acids (KZ/acid granule) using a high-shear mixer. Dissolution tests of the KZ/acid granule resulted in highly enhanced solubility under non-sink conditions. Adding water-soluble acids, such as citric acid (CA) and tartaric acid, resulted in more than 8-fold higher dissolution at pH 6.0 compared to that of KZ only. The granules containing citric acid (KZ/CA granule) improved the dissolution of KZ after oral administration to rats under low gastric acid conditions, where the bioavailability of the KZ/CA granules at elevated gastric pH was comparable with that of KZ only at gastric acidic pH. The incorporation of organic acids would result in effective therapeutic outcomes independent of gastric pH in patients. In addition, higher bioavailability of KZ was observed after oral administration of KZ/CA granules under gastric acidic pH conditions than that of KZ alone. Thus, CA improved the dissolution and absorption rate of KZ after oral administration.


Asunto(s)
Ácido Cítrico/administración & dosificación , Absorción Intestinal/efectos de los fármacos , Cetoconazol/farmacocinética , Estómago/efectos de los fármacos , Administración Oral , Animales , Disponibilidad Biológica , Química Farmacéutica , Ácido Cítrico/química , Ácido Gástrico/metabolismo , Mucosa Gástrica/metabolismo , Concentración de Iones de Hidrógeno , Cetoconazol/administración & dosificación , Cetoconazol/sangre , Cetoconazol/química , Masculino , Inhibidores de la Bomba de Protones/farmacología , Ratas Wistar , Solubilidad , Tartratos/química , Tecnología Farmacéutica/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA